Extensive research is ongoing that concentrates on finding therapies to enhance CNS regeneration after spinal cord injury (SCI) and to cure paralysis. This review sheds light on the role of the FGFR pathway in the injured spinal cord and discusses various therapies that use FGFR activating ligands to promote regeneration after SCI. We discuss studies that use peripheral nerve grafts or Schwann cell grafts in combination with FGF1 or FGF2 supplementation. Most of these studies show evidence that these therapies successfully enhance axon regeneration into the graft. Further they provide evidence for partial recovery of sensory function shown by electrophysiology and motor activity evidenced by behavioural data. We also present one study that indicates that combination with additional, synergistic factors might further drive the system towards functional regeneration. In essence, this review summarises the potential of nerve and cell grafts combined with FGF1/2 supplementation to improve outcome even after severe spinal cord injury.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jmmr1Q
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2oYRz8x via IFTTT
-
© 2011 IRA/NCTE. All rights reserved. materials may be reproduced for educational purposes. Book Review Template Let's explore some prop...
-
Shortest path problem has been a classic issue. Even more so difficulties remain involving large data environment. Current research on short...
-
by Fangzhou Li, Zhiming Feng, Peng Li, Zhen You The study of urban spatial interaction is closely linked to that of economic geography, urb...
-
Abstract Psoriasis is a multifactorial inflammatory disorder, in which the inflammation affects not only the skin but also the other inter...
-
Abstract Background Individuals with advanced, incurable cancer often experience high physical and psychological symptom burden. Family an...
-
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor British Journal of Canc...
-
Class-switch recombination (CSR) alters the Ig isotype to diversify antibody effector functions. IgD CSR is a rare event, and its regulation...
-
ACS Nano DOI: 10.1021/acsnano.6b06114 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2kOsUGq via...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου